Securities code: 688336 securities abbreviation: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Announcement No.: 2022-008 Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Announcement on the resolution of the fifth meeting of the Fourth Board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of directors
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) the notice of the fifth meeting of the Fourth Board of directors of Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as “the company”) was sent by telephone, e-mail and personal delivery on February 11, 2022. The meeting was held by means of communication voting on February 16, 2022. Seven directors should be present at the meeting, and there are actually seven directors. The meeting is presided over by Mr. Lou Jing, chairman of the board. The convening and convening procedures of this meeting, 16 the qualifications of participants and the procedures for discussion and voting comply with the relevant provisions of the company law of the people’s Republic of China (hereinafter referred to as the “company law”) and the articles of association of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as the “articles of association”), and the resolutions of the meeting are legal and effective.
2、 Deliberations of the board meeting
After careful deliberation and voting by the directors present, the following proposals were considered and adopted:
(I) the proposal on granting restricted shares to incentive objects and reserving some restricted shares in the 2021 restricted stock incentive plan was reviewed and approved
In accordance with the relevant provisions of the measures for the administration of equity incentive of listed companies (hereinafter referred to as the “measures”), the 2021 restricted stock incentive plan (Draft) of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as the “incentive plan”) and the authorization of the company’s first extraordinary general meeting in 2021, The company believes that the reserved restricted stock grant conditions specified in the restricted stock incentive plan in 2021 have been met, and agrees to grant 427100 restricted shares to 33 incentive objects with February 16, 2022 as the grant date and the grant price of 4 yuan / share.
The independent directors expressed their independent opinions on the above proposal.
The incentive objects to be granted rights and interests this time have the qualifications specified in the company law, the articles of association and other laws, regulations and normative documents, meet the conditions of incentive objects specified in the administrative measures, the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange and other documents, meet the scope of incentive objects specified in the incentive plan, and there are no independent directors supervisor. As the incentive object to be granted rights and interests this time, its subject qualification is legal and effective, and meets the conditions of being granted rights and interests.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) on February 17, 2022 Announcement on granting restricted shares to incentive objects and reserving some restricted shares in the 2021 restricted stock incentive plan (Announcement No.: 2022-007). Voting results: 7 in favor, 0 against and 0 abstention. The proposal is passed.
It is hereby announced.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) board of directors of Pharmaceutical (Shanghai) Co., Ltd. February 17, 2022
